Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR422459 subretinal gene therapy safety study in Stargardt macular degeneration
NL-OMON43680Phase 1Withdrawn
- Sponsor
- Sanofi
- Start
- Feb 2016
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SAR422459 in Fundus Flavimaculatus (FF), sponsored by Sanofi. Planned start Feb 2016; status: withdrawn.
02
Drugs
SAR422459
03
Conditions
Fundus Flavimaculatus (FF)
Beyond the preview
Go deeper on NL-OMON43680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43680.